Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMI-0100 in Healthy Smokers with LPS Challenge
NCT02515396Phase 1Unknown
- Sponsor
- Moerae Matrix
- Start
- Jul 2015
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MMI-0100 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Moerae Matrix. Primary endpoints: Adverse Events at 6 weeks and Cytokine Biomarkers at 6 weeks. Status: unknown.
02
Drugs
MMI-0100
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02515396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515396.